BIO Girds for Multi-Front Protection of Vulnerable Biotech Companies
Market Turmoil, Manipulation Could Slow Access To Critical New Therapies, Renewable Fuels
A Message From BIO's President and CEO, Jim Greenwood
The current national financial crisis could have a lasting impact on the biotechnology industry Read the statement
BIO Bolsters Its Companies and Funding Streams for Biotech Start-ups
When Times Are Tough, Sharpen Your Skills
To compete in today's challenging environment you have to be at your very best. BIO's Advanced Business Development course can help you hone your skills in valuation, due diligence, negotiation and contracts to take your company (and your career) to the next level. Sign up for the course
BIO Lauds SEC Crack-down on "naked" Short-selling and other Market Manipulations
Biotech Start-ups are especially vulnerable to false rumors.
Read BIO's Letter to the SEC and the Press Release
BIO Members Await Conference Agreement on SBIR Reform and Extension
The Bill Could Reinstate SBIR Eligibility to Some Promising New Biotech Companies Read BIO's Hopes and Cures Blog for the latest developments.
BIO Lauds Senate Passage of Strengthened Two-Year R&D Credit
The Biotechnology Industry Organization (BIO) today lauded U.S. Senate passage of a 2-year extension of the federal research and development (R&D) tax credit and urged the House to pass the package when it is considered on Friday. Read the news release
United States Department of Agriculture's (USDA's) Animal and Plant Health Inspection Service (APHIS) releases a proposed rule to revise its regulations (7CFR Part 340) regarding agricultural biotechnology.
Policy Updates
Small Business Innovation Research Grants (SBIR)
Not sure what the SBIR issue is? Check out our Hopes and Cures Blog, and find out why stamping out SBIR will also stamp out hope for cures.
